David A. Cheresh

59.2k total citations · 20 hit papers
245 papers, 48.7k citations indexed

About

David A. Cheresh is a scholar working on Immunology and Allergy, Molecular Biology and Cancer Research. According to data from OpenAlex, David A. Cheresh has authored 245 papers receiving a total of 48.7k indexed citations (citations by other indexed papers that have themselves been cited), including 153 papers in Immunology and Allergy, 147 papers in Molecular Biology and 69 papers in Cancer Research. Recurrent topics in David A. Cheresh's work include Cell Adhesion Molecules Research (153 papers), Angiogenesis and VEGF in Cancer (56 papers) and Protease and Inhibitor Mechanisms (45 papers). David A. Cheresh is often cited by papers focused on Cell Adhesion Molecules Research (153 papers), Angiogenesis and VEGF in Cancer (56 papers) and Protease and Inhibitor Mechanisms (45 papers). David A. Cheresh collaborates with scholars based in United States, Italy and Canada. David A. Cheresh's co-authors include Peter C. Brooks, Sara M. Weis, Jay S. Desgrosellier, John Hood, Dwayne G. Stupack, Richard A.F. Clark, Glen R. Nemerow, Richard Klemke, Brian P. Eliceiri and Ralph A. Reisfeld and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

David A. Cheresh

243 papers receiving 47.7k citations

Hit Papers

Integrins in cancer: biological impli... 1987 2026 2000 2013 2009 1994 1994 1993 2002 500 1000 1.5k 2.0k 2.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Integrins in cancer: biological implications and therapeutic opportunities
    2009 2.9k citations Jay S. Desgrosellier, David A. Cheresh profile →
  2. Requirement of Vascular Integrin α v β 3 for Angiogenesis
    1994 2.5k citations Peter C. Brooks, David A. Cheresh et al. Science profile →
  3. Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
    1994 1.9k citations Peter C. Brooks, Ralph A. Reisfeld et al. Cell profile →
  4. Integrins αvβ3 and αvβ5 promote adenovirus internalization but not virus attachment
    1993 1.8k citations David A. Cheresh et al. Cell profile →
  5. Role of integrins in cell invasion and migration
    2002 1.4k citations John Hood, David A. Cheresh profile →
  6. Tumor angiogenesis: molecular pathways and therapeutic targets
    2011 1.4k citations Sara M. Weis, David A. Cheresh Nature Medicine profile →
  7. Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3
    1996 1.3k citations Peter C. Brooks, Staffan Strömblad et al. Cell profile →
  8. Definition of Two Angiogenic Pathways by Distinct α v Integrins
    1995 1.1k citations Peter C. Brooks, Judith A. Varner et al. Science profile →
  9. Regulation of Cell Motility by Mitogen-activated Protein Kinase
    1997 1.1k citations Richard Klemke, David A. Cheresh et al. profile →
  10. Pathophysiological consequences of VEGF-induced vascular permeability
    2005 708 citations Sara M. Weis, David A. Cheresh Nature profile →
  11. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin.
    1995 701 citations Peter C. Brooks, Staffan Strömblad et al. profile →
  12. Detection of tumor angiogenesis in vivo by αvβ3-targeted magnetic resonance imaging
    1998 689 citations David A. Cheresh, Mark D. Bednarski et al. Nature Medicine profile →
  13. Tumor Regression by Targeted Gene Delivery to the Neovasculature
    2002 661 citations John Hood, Mark D. Bednarski et al. Science profile →
  14. Selective Requirement for Src Kinases during VEGF-Induced Angiogenesis and Vascular Permeability
    1999 646 citations John Hood, David A. Cheresh et al. profile →
  15. CAS/Crk Coupling Serves as a “Molecular Switch” for Induction of Cell Migration
    1998 596 citations Richard Klemke, Peter C. Brooks et al. profile →
  16. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance
    2015 538 citations Laetitia Seguin, Jay S. Desgrosellier et al. profile →
  17. The role of αv integrins during angiogenesis: insights into potential mechanisms of action and clinical development
    1999 537 citations David A. Cheresh et al. profile →
  18. Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor.
    1987 521 citations David A. Cheresh et al. profile →
  19. Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity
    1998 502 citations Peter C. Brooks, Tami L von Schalscha et al. Cell profile →
  20. A role for VEGF as a negative regulator of pericyte function and vessel maturation
    2008 501 citations David J. Shields, Lisette M. Acevedo et al. Nature profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David A. Cheresh United States 109 28.3k 18.3k 10.6k 10.3k 7.6k 245 48.7k
Richard O. Hynes United States 132 33.4k 1.2× 31.3k 1.7× 11.4k 1.1× 10.4k 1.0× 18.6k 2.4× 365 73.6k
Joan S. Brugge United States 111 25.6k 0.9× 7.4k 0.4× 5.1k 0.5× 10.2k 1.0× 9.5k 1.3× 259 41.9k
Carl‐Henrik Heldin Sweden 132 41.7k 1.5× 5.1k 0.3× 8.9k 0.8× 14.1k 1.4× 6.7k 0.9× 494 62.7k
Hynda K. Kleinman United States 102 16.4k 0.6× 11.0k 0.6× 5.6k 0.5× 6.3k 0.6× 8.3k 1.1× 349 38.2k
Rupert Timpl Germany 124 20.4k 0.7× 22.7k 1.2× 8.3k 0.8× 3.7k 0.4× 14.4k 1.9× 526 49.4k
Harold F. Dvorak United States 101 24.4k 0.9× 5.5k 0.3× 10.0k 0.9× 10.0k 1.0× 3.7k 0.5× 279 47.8k
Elisabetta Dejana Italy 113 22.7k 0.8× 8.3k 0.5× 4.6k 0.4× 5.6k 0.5× 8.4k 1.1× 389 44.0k
Francisco Sánchez‐Madrid Spain 99 16.7k 0.6× 10.3k 0.6× 6.4k 0.6× 5.5k 0.5× 3.9k 0.5× 525 39.9k
Mark H. Ginsberg United States 108 16.5k 0.6× 21.4k 1.2× 3.9k 0.4× 3.4k 0.3× 12.8k 1.7× 359 41.6k
Karl Tryggvason Sweden 96 15.1k 0.5× 9.8k 0.5× 6.8k 0.6× 4.8k 0.5× 4.9k 0.6× 384 34.3k

Countries citing papers authored by David A. Cheresh

Since Specialization
Citations

This map shows the geographic impact of David A. Cheresh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David A. Cheresh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David A. Cheresh more than expected).

Fields of papers citing papers by David A. Cheresh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David A. Cheresh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David A. Cheresh. The network helps show where David A. Cheresh may publish in the future.

Co-authorship network of co-authors of David A. Cheresh

This figure shows the co-authorship network connecting the top 25 collaborators of David A. Cheresh. A scholar is included among the top collaborators of David A. Cheresh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David A. Cheresh. David A. Cheresh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shepard, Ryan M., Tami Von Schalscha, Stephen J. McCormack, et al.. (2025). Macrophage-Engaging IgG4 Antibody Triggers Cytotoxicity against Integrin αvβ3+ Cancers. Molecular Cancer Therapeutics. 25(3). 448–456.
2.
Schalscha, Tami Von, Chen Qian, Ryan M. Shepard, et al.. (2025). Targeting Pancreatic Cancer Cell Stemness by Blocking Fibronectin-Binding Integrins on Cancer-Associated Fibroblasts. Cancer Research Communications. 5(1). 195–208. 2 indexed citations
3.
Testa, Anna, Stephen Lin, Tami Von Schalscha, et al.. (2023). Targeting the αVβ3/NgR2 pathway in neuroendocrine prostate cancer. Matrix Biology. 124. 49–62. 6 indexed citations
4.
Wettersten, Hiromi I., Sara M. Weis, Paulina Pathria, et al.. (2019). Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression. Cancer Research. 79(19). 5048–5059. 25 indexed citations
5.
Carlson, Patrick, Candice Alexandra Grzelak, Alexander Barrett, et al.. (2019). Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nature Cell Biology. 21(2). 238–250. 189 indexed citations
6.
Lapek, John D., Ken Fujimura, Ján Strnádel, et al.. (2018). Pseudopodium-enriched atypical kinase 1 mediates angiogenesis by modulating GATA2-dependent VEGFR2 transcription. Cell Discovery. 4(1). 26–26. 20 indexed citations
7.
Seguin, Laetitia, Maria F. Camargo, Hiromi I. Wettersten, et al.. (2017). Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers. Cancer Discovery. 7(12). 1464–1479. 84 indexed citations
8.
Espinosa‐Díez, Cristina, Namita Chatterjee, Rebecca Ruhl, et al.. (2016). MicroRNA regulation of endothelial TREX1 reprograms the tumour microenvironment. Nature. 18 indexed citations
9.
Franovic, Aleksandra, Kathryn C. Elliott, Laetitia Seguin, et al.. (2015). Glioblastomas Require Integrin αvβ3/PAK4 Signaling to Escape Senescence. Cancer Research. 75(21). 4466–4473. 34 indexed citations
10.
Murphy, Eric A., Bharat K. Majeti, Rajesh Mukthavaram, et al.. (2011). Targeted Nanogels: A Versatile Platform for Drug Delivery to Tumors. Molecular Cancer Therapeutics. 10(6). 972–982. 62 indexed citations
11.
Garmy‐Susini, Barbara, Christie J. Avraamides, Michael C. Schmid, et al.. (2010). Integrin α4β1 Signaling Is Required for Lymphangiogenesis and Tumor Metastasis. Cancer Research. 70(8). 3042–3051. 134 indexed citations
12.
Anand, Sudarshan, Bharat K. Majeti, Lisette M. Acevedo, et al.. (2010). MicroRNA-132–mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nature Medicine. 16(8). 909–914. 418 indexed citations
13.
Ricono, Jill M., Miller Huang, Leo A. Barnes, et al.. (2009). Specific Cross-talk between Epidermal Growth Factor Receptor and Integrin αvβ5 Promotes Carcinoma Cell Invasion and Metastasis. Cancer Research. 69(4). 1383–1391. 116 indexed citations
14.
Shields, David J., Sherry Niessen, Eric A. Murphy, et al.. (2009). RBBP9: A tumor-associated serine hydrolase activity required for pancreatic neoplasia. Proceedings of the National Academy of Sciences. 107(5). 2189–2194. 52 indexed citations
15.
Doukas, John, Wolfgang Wrasidlo, Glenn Noronha, et al.. (2006). Phosphoinositide 3-kinase γ/δ inhibition limits infarct size after myocardial ischemia/reperfusion injury. Proceedings of the National Academy of Sciences. 103(52). 19866–19871. 108 indexed citations
16.
Mitra, Satyajit K., John J. Molina, Datsun A. Hsia, et al.. (2005). Focal adhesion kinase (FAK) activity promotes tumor growth and neo-vascularization via upregulation of angiogenic factors. Cancer Research. 65. 475–475. 3 indexed citations
17.
Hood, John, Mark D. Bednarski, Ricardo F. Frausto, et al.. (2002). Tumor Regression by Targeted Gene Delivery to the Neovasculature. Science. 296(5577). 2404–2407. 661 indexed citations breakdown →
18.
Brooks, Peter C., Staffan Strömblad, Luraynne C. Sanders, et al.. (1996). Localization of Matrix Metalloproteinase MMP-2 to the Surface of Invasive Cells by Interaction with Integrin αvβ3. Cell. 85(5). 683–693. 1318 indexed citations breakdown →
19.
Cheresh, David A. & Robert P. Mecham. (1994). Integrins : molecular and biological responses to the extracellular matrix. Academic Press eBooks. 59 indexed citations
20.
Cheresh, David A., et al.. (1982). Maximizing differences in the concanavalin A-induced blastogenic responses of lymphocytes from breast cancer patients and controls by the use of alpha-methyl-D-mannoside.. PubMed. 68(1). 68–9.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Richard O. Hynes Breakdown of academic impact, for papers by Joan S. Brugge Breakdown of academic impact, for papers by Carl‐Henrik Heldin Breakdown of academic impact, for papers by Hynda K. Kleinman Breakdown of academic impact, for papers by Rupert Timpl Breakdown of academic impact, for papers by Harold F. Dvorak Breakdown of academic impact, for papers by Elisabetta Dejana Breakdown of academic impact, for papers by Francisco Sánchez‐Madrid Breakdown of academic impact, for papers by Mark H. Ginsberg Breakdown of academic impact, for papers by Karl Tryggvason
Rankless by CCL
2026